Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ)
Shanghai, CN
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., formerly known as Yuwell Medical, was established in 1998 and is headquartered in Shanghai, China. The company operates globally, manufacturing and distributing a diverse array of medical devices in both domestic and international markets. Its extensive product catalog includes sophisticated respiratory therapy solutions, such as ventilators, humidifiers, oxygen generators, nebulizers, and advanced non-invasive ventilator data management systems. Yuwell also offers comprehensive chronic disease monitoring systems, featuring sphygmomanometers, blood glucose meters, pulse oximeters, thermometers, stethoscopes, alongside general practice diagnostic tools and in-hospital blood glucose management platforms. Furthermore, the company provides cutting-edge imaging diagnosis and treatment solutions, including ultrasound diagnostic imaging, interventional, and minimally invasive technologies. Its offerings extend to infection control and disinfection products, as well as specialized ophthalmology and vision care items like microscopes, eye surgical instruments, ophthalmoscopes, synoptophores, and keratometers. Defibrillator monitors are also part of their product range. Additionally, Yuwell supplies a broad spectrum of durable medical equipment and consumables, encompassing basic and microsurgical tools, instruments for ENT and orthopedics, endoscopic devices, dental appliances, acupuncture and electronic acupuncture products, absorbable sutures, and venous indwelling needles.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.01% | -3.96% | -10.10% | -31.71% | -25.97% | -30.83% | -29.61% | -20.49% | -12.34% | +28.36% | +1,418.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+4.5% Q1'26: -2.7% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-18.2% Q1'26: -31.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+10.8% Q1'26: +24.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+14.5% ★ Q1'26: +19.6% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+7.7% ★ Q1'26: +11.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.47× ★ Q1'26: 0.37× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 8 Rev. Ana. 8 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.10B
est: 2.07B (+1.8%)
|
2.64B
est: 2.80B (-5.6%)
|
3.54B
est: 3.49B (+1.4%)
|
4.18B
est: 4.21B (-0.7%)
|
4.64B
est: 4.67B (-0.7%)
|
6.73B
est: 6.73B (0.0%)
|
6.89B
est: 7.07B (-2.5%)
|
7.10B
est: 7.05B (+0.7%)
|
7.97B
est: 8.21B (-2.9%)
|
7.57B
est: 8.08B (-6.3%)
|
7.90B
est: 8.37B (-5.6%)
|
8.66B
8.53B – 8.80B
+3.5% YoY
|
9.65B
8.92B – 10.60B
+11.5% YoY
|
10.81B
10.29B – 11.46B
+11.9% YoY
|
| EBITDA |
428.38M
est: 531.05M (-19.3%)
|
562.17M
est: 718.37M (-21.7%)
|
719.82M
est: 897.31M (-19.8%)
|
804.51M
est: 1.08B (-25.7%)
|
890.70M
est: 1.20B (-25.7%)
|
2.17B
est: 1.73B (+25.6%)
|
1.68B
est: 1.82B (-7.6%)
|
1.59B
est: 1.81B (-12.5%)
|
2.24B
est: 2.11B (+6.0%)
|
1.63B
est: 1.85B (-12.2%)
|
1.45B
est: 1.92B (-24.2%)
|
1.98B
1.95B – 2.02B
+3.5% YoY
|
2.21B
2.04B – 2.43B
+11.5% YoY
|
2.48B
2.36B – 2.63B
+11.9% YoY
|
| EBIT |
375.96M
est: 476.09M (-21.0%)
|
499.76M
est: 644.02M (-22.4%)
|
639.58M
est: 804.44M (-20.5%)
|
713.86M
est: 970.53M (-26.4%)
|
794.42M
est: 1.08B (-26.1%)
|
2.01B
est: 1.55B (+29.7%)
|
1.49B
est: 1.63B (-8.5%)
|
1.39B
est: 1.62B (-14.6%)
|
2.03B
est: 1.89B (+7.3%)
|
1.41B
est: 1.61B (-12.2%)
|
1.14B
est: 1.67B (-31.6%)
|
1.73B
1.70B – 1.76B
+3.5% YoY
|
1.93B
1.78B – 2.11B
+11.5% YoY
|
2.16B
2.05B – 2.29B
+11.9% YoY
|
| Net Income |
364.34M
est: 452.26M (-19.4%)
|
499.82M
est: 507.01M (-1.4%)
|
592.03M
est: 626.05M (-5.4%)
|
727.15M
est: 717.30M (+1.4%)
|
752.57M
est: 760.79M (-1.1%)
|
1.76B
est: 1.70B (+3.4%)
|
1.48B
est: 1.48B (+0.4%)
|
1.60B
est: 1.46B (+9.1%)
|
2.40B
est: 2.49B (-3.6%)
|
1.81B
est: 1.96B (-8.1%)
|
1.48B
est: 1.76B (-15.9%)
|
1.60B
1.47B – 1.68B
-9.1% YoY
|
1.86B
1.51B – 2.43B
+16.1% YoY
|
2.15B
2.01B – 2.32B
+15.4% YoY
|
| SGA |
429.99M
est: 408.49M (+5.3%)
|
478.53M
est: 552.58M (-13.4%)
|
620.03M
est: 690.23M (-10.2%)
|
783.77M
est: 832.73M (-5.9%)
|
896.27M
est: 922.41M (-2.8%)
|
1.11B
est: 1.33B (-16.2%)
|
1.33B
est: 1.40B (-4.5%)
|
1.45B
est: 1.39B (+4.2%)
|
1.50B
est: 1.62B (-7.6%)
|
1.79B
est: 1.77B (+1.3%)
|
2.14B
est: 1.83B (+16.8%)
|
1.89B
1.86B – 1.92B
+3.5% YoY
|
2.11B
1.95B – 2.32B
+11.5% YoY
|
2.36B
2.25B – 2.50B
+11.9% YoY
|
| EPS |
0.41
est: 0.45 (-9.6%)
|
0.53
est: 0.51 (+4.3%)
|
0.59
est: 0.63 (-6.0%)
|
0.73
est: 0.72 (+1.5%)
|
0.75
est: 0.76 (-1.7%)
|
1.75
est: 1.71 (+2.6%)
|
1.49
est: 1.48 (+0.7%)
|
1.61
est: 1.47 (+9.8%)
|
2.41
est: 2.49 (-3.3%)
|
1.81
est: 1.97 (-8.0%)
|
1.48
est: 1.76 (-16.1%)
|
1.60
1.47 – 1.68
-9.1% YoY
|
1.86
1.51 – 2.43
+16.1% YoY
|
2.15
2.02 – 2.32
+15.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.15% | 53.7K | 0.65% |
| 2 | HSBC MSCI China A UCITS ETF HMCT.L | 0.10% | 130.0K | 0.30% |
| 3 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.10% | 368.1K | 0.44% |
| 4 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.05% | 8.9K | 0.65% |
| 5 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.04% | 27.6K | 0.55% |
| 6 | State Street SPDR S&P China ETF GXC | 0.02% | 97.8K | 0.59% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 214.0K | 0.19% |
| 8 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 2.29M | 0.07% |
| 9 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 54.9K | 0.49% |
| 10 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.01% | 6.5K | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Caihao Yu | Deputy General Manager | — | male |
| Hongzhe Zheng | Deputy General Manager | — | male |
| Lihua Liu | Financial Director | — | female |
| Nanxuan Xu | Deputy General Manager | — | male |
| Qun Wu | GM & Chairman | — | male |
| Ruijie Wang | Director & Board Secretary | — | female |
| Shuai Zhao | Deputy GM & Non Independent Director | — | male |
| Wei Jing | Deputy General Manager | — | male |
| Yingfang Lu | Supervisory Board Chairman | — | male |
| Yonghong Shi | Accounting Supervisor | — | — |
| Zhang Yong | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002223.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
